AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 75 filers reported holding AVADEL PHARMACEUTICALS PLC in Q2 2018. The put-call ratio across all filers is 1.57 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $764,000 | +2082.9% | 151,585 | +1710.6% | 0.00% | – |
| Q3 2019 | $35,000 | -94.4% | 8,372 | -96.1% | 0.00% | -100.0% |
| Q2 2019 | $620,000 | -49.1% | 213,951 | -74.6% | 0.00% | -40.0% |
| Q1 2019 | $1,217,000 | -56.4% | 843,975 | -21.9% | 0.01% | -64.3% |
| Q4 2018 | $2,790,000 | -43.3% | 1,080,877 | -3.5% | 0.01% | -30.0% |
| Q3 2018 | $4,917,000 | -39.7% | 1,120,215 | -15.8% | 0.02% | -42.9% |
| Q2 2018 | $8,157,000 | -32.1% | 1,330,835 | -19.2% | 0.04% | -32.7% |
| Q1 2018 | $12,013,000 | -11.4% | 1,648,037 | -0.4% | 0.05% | -11.9% |
| Q4 2017 | $13,563,000 | -22.0% | 1,653,973 | -0.1% | 0.06% | -23.4% |
| Q3 2017 | $17,379,000 | -5.8% | 1,655,273 | -1.0% | 0.08% | -8.3% |
| Q2 2017 | $18,444,000 | +25.0% | 1,672,207 | +9.7% | 0.08% | +23.5% |
| Q1 2017 | $14,756,000 | – | 1,524,300 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WEALTH EFFECTS LLC | 2,305,017 | $18,625,000 | 7.73% |
| COWEN AND COMPANY, LLC | 3,732,778 | $30,161,000 | 2.74% |
| GENDELL JEFFREY L | 2,446,299 | $19,766,000 | 1.60% |
| Asymmetry Capital Management, L.P. | 369,134 | $2,983,000 | 1.58% |
| Vivo Capital, LLC | 2,937,093 | $23,732,000 | 1.43% |
| Samsara BioCapital, LLC | 659,409 | $5,328,000 | 1.03% |
| Altium Capital Management LP | 440,589 | $3,560,000 | 0.98% |
| Knott David M Jr | 258,198 | $2,086,000 | 0.71% |
| RTW INVESTMENTS, LP | 5,741,939 | $46,395,000 | 0.68% |
| FRAZIER MANAGEMENT LLC | 951,814 | $7,691,000 | 0.59% |